Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression
Ignacio Iñigo-Marco1,2,3 and Marta M. Alonso1,2,3
1Navarra’s Health Research Institute (IDISNA) Pamplona, Spain.
2Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Spain.
3Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain.
Address correspondence to: Marta M. Alonso, Department of Pediatrics, Clínica Universidad de Navarra, CIMA Building, Avd. Pio XII, 55 Pamplona, Spain. Phone: 34.948194700.1017; Email: mmalonso@unav.es.
Find articles by Iñigo-Marco, I. in: JCI | PubMed | Google Scholar
1Navarra’s Health Research Institute (IDISNA) Pamplona, Spain.
2Program in Solid Tumors, Foundation for Applied Medical Research, Pamplona, Spain.
3Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain.
Address correspondence to: Marta M. Alonso, Department of Pediatrics, Clínica Universidad de Navarra, CIMA Building, Avd. Pio XII, 55 Pamplona, Spain. Phone: 34.948194700.1017; Email: mmalonso@unav.es.
Find articles by Alonso, M. in: JCI | PubMed | Google Scholar
First published November 11, 2019 - More info
J Clin Invest. 2019;129(12):5086–5088. https://doi.org/10.1172/JCI133115.
© 2019 American Society for Clinical Investigation
Tumor-induced immunosuppression is a common obstacle for cancer treatment. Adrenergic signaling triggered by chronic stress participates in the creation of an immunosuppressive microenvironment by promoting myeloid-derived suppressor cell (MDSC) proliferation and activation. In this issue of the JCI, Mohammadpour et al. elegantly delve into the mechanisms underlying MDSC contribution to tumor development. They used in vitro and in vivo mouse models to demonstrate that chronic stress results in MDSC accumulation, survival, and immune-inhibitory activity. Of therapeutic relevance, the authors showed that propranolol, a commonly prescribed β-blocker, can reduce MDSC immunosuppression and enhance the effect of other cancer therapies.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)